NUVALENT INC-A (NUVL)
US6707031075 - Common Stock
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024
NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the first quarter of 2024.
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent (NUVL) Shares Cross Below 200 DMA
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent lung cancer candidate gets FDA breakthrough therapy status (NASDAQ:NUVL)
Nuvalent's lung cancer drug NVL-520 receives breakthrough therapy designation from the FDA for ROS1-positive metastatic NSCLC treatment.
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Baird starts Nuvalent at outperform, cites potential of lead assets (NASDAQ:NUVL)
Baird has initiated coverage of Nuvalent (NUVL) with an outperform rating, citing the potential of its two lead assets, NVL-520 and NVL-655, in the treatment of
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Notable Thursday Option Activity: NUVL, RKLB, WMT
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Notable Thursday Option Activity: ISRG, CABA, NUVL
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Noteworthy Friday Option Activity: NUVL, PTEN, CC
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Noteworthy Tuesday Option Activity: DAL, CRC, NUVL
Notable Thursday Option Activity: VOYA, NUVL, IOVA
Notable Friday Option Activity: COGT, NUVL, MDB
Nuvalent GAAP EPS of -$0.59 misses by $0.01 (NASDAQ:NUVL)
Read about Nuvalent's Q3 financial results, including a missed earnings per share (EPS) target.
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent says Matthew Shair sells 91.7Kof class A common shares in co (NASDAQ:NUVL)
Nuvalent (NUVL) insider, Matthew Shair, sold 91.7K class A common shares at $50.63-$51.23 per share on Oct 24, according to a Rule 10b5-1 trading plan.
Nuvalent director sells $4.65M in common stock (NASDAQ:NUVL)
Matthew Shair, director of Nuvalent, sold over $4 million worth of company shares and currently holds 240,522 shares.
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.
Commit To Purchase Nuvalent At $50, Earn 47.4% Annualized Using Options
Investors Snatch NUVL 6.3% Cheaper Than Its Secondary Stock Offering
Why Nuvalent Stock Tanked on Tuesday
The dilution monster stalked the company following the announcement of a new capital-raising effort.
Notable Tuesday Option Activity: AVAV, POWW, NUVL
Nuvalent prices $300 million stock offering
Nuvalent announces pricing of public offering, expecting to raise $300 million by offering 5.36 million shares of Class A common stock at $56 per share.
Nuvalent Announces Pricing of Public Offering of Common Stock
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent Announces Public Offering of Common Stock
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent's drug shows promise in lung cancer patients in preliminary phase 1 data
Nuvalent reported encouraging preliminary data for its drug NVL-655 in heavily pre-treated non-small cell lung cancer patients, showing potential activity. Read more here
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Why Nuvalent Stock Skyrocketed 35% This Week
Nuvalent announced favorable preliminary data in a clinical trial for its lung cancer drug. Here's what investors need to know.